Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

Podrobná bibliografie
Hlavní autoři:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
Médium:	Journal article
Jazyk:	English
Vydáno:	2002

Podobné jednotky

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Autor: Eaton, C, a další
Vydáno: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Autor: Eaton, C, a další
Vydáno: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
Autor: Holen, I, a další
Vydáno: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Autor: Holen, I, a další
Vydáno: (2002)

Role of osteoprotegerin (OPG) in cancer.
Autor: Holen, I, a další
Vydáno: (2006)

The role of osteoprotegerin in breast and prostate cancer
Autor: Holen, I, a další
Vydáno: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
Autor: Holen Ingunn, a další
Vydáno: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Autor: Shipman, C, a další
Vydáno: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
Autor: Lili Zhang, a další
Vydáno: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Autor: Shipman, C, a další
Vydáno: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Autor: Shipman, C, a další
Vydáno: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
Autor: Gamal B Mohamed, a další
Vydáno: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Autor: Waterman, E, a další
Vydáno: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
Autor: Miles, L, a další
Vydáno: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
Autor: Noura N. Alraouji, a další
Vydáno: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
Autor: Riham Eid, a další
Vydáno: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Autor: Shipman, C, a další
Vydáno: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
Autor: Siamak Kazemi-Sufi, a další
Vydáno: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
Autor: Nyambo, R, a další
Vydáno: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Autor: Nyambo, R, a další
Vydáno: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
Autor: Chan Kai-Ming, a další
Vydáno: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
Autor: Syed Muhammad Muneeb Akhtar, a další
Vydáno: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
Autor: Croucher, P, a další
Vydáno: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
Autor: Yao Jing, a další
Vydáno: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
Autor: Saba Tariq, a další
Vydáno: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Autor: Yosra Azizpour, a další
Vydáno: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Autor: Yosra Azizpour, a další
Vydáno: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
Autor: Ruffion, A, a další
Vydáno: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
Autor: Lara Absil, a další
Vydáno: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
Autor: Indra Wijaya, a další
Vydáno: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Autor: Croucher, P, a další
Vydáno: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2001)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
Autor: Lane Denis, a další
Vydáno: (2012-11-01)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
Autor: Shirly Elisa Tedjasaputra, a další
Vydáno: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
Autor: Salvador Atilano-Miguel, a další
Vydáno: (2022-01-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Autor: Martin Widschwendter, a další
Vydáno: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
Autor: Cross, N, a další
Vydáno: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
Autor: Cross, N, a další
Vydáno: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Autor: Vanderkerken, K, a další
Vydáno: (2003)